Loading
A phase 2 trial of Padeliporfin in Prostate cancer, run by Steba Biotech S.A., completed.
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer is a phase 2 interventional study registered as NCT03315754 by Steba Biotech S.A., with 50 participants recorded, started 2017-10-02 and reaching its primary completion in 2020-11-02. Interventions recorded: TOOKAD Soluble 4 mg/kg. Conditions recorded: Localized Prostate Cancer.
Linked to the drug Padeliporfin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
50 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2023-08-02), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Participants With Negative Biopsy for Gleason Score 7 (Gleason Grade 4 or 5) Prostate Cancer on 12-month Post-treatmentprimary | 12 Months Follow up PP Group | 44 | 37 participants | - | - | link |
| 12 Months Follow up ITT Group | 50 | 38 participants |
Shares Steba Biotech, Padeliporfin, Prostate cancer and the tag pipeline.
Shares Steba Biotech, Padeliporfin, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, intermediate risk, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.